![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, December 04, 2012 3:05:35 PM
High revenue, high growth, and no profit:
1. Takeover target. More mature company will implement cost-cutting procedures. Good for some longs, depending on our entry point.
2. Continues to be the dilution machine in order to fund operations. Worst case scenario and not good for longs, especially for those who got in early.
High revenue, high grow, and profit:
1. Self-sustaining company and stock will eventually take off to reflect that. Good for longs.
2. Takeover target at a premium price. Good for longs.
Muscle Pharm has to reduce its cost of goods sold (cogs) and/or cut operating cost. We know the revenue is there.
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM